Neutropenic Patients
Conditions
Brief summary
The aim of the present work is to study the protein expressions profiles of neutropenic patients (with a high risk of invasive mycosis) who developed - versus who did not develop invasive mycosis (principally aspergillosis and candidosis) in order to identify biomarkers for the diagnosis, prognosis and /or prediction of invasive mycosis.
Interventions
OTHERSamples taken at the clinical hematology unit
Sponsors
Centre Hospitalier Universitaire Dijon
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
OTHER
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
14 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* \- Patients with malignant haemopathy who received chemotherapy likely to lead to severe neutropenia (PN\<500/mm3) for a foreseeable period of 10 days. * Patients aged 14 years or older (no upper age limit) * Patients with malignant haemopathy who received an autologous marrow graft. * Patients with severe idiopathic medullar aplasia (PN\<500/mm3) who need to be hospitalised for at least 10 days consecutively (with or without immunosuppressant treatment). * Patients who have provided written informed consent to participate in this study.
Exclusion criteria
* Patients who received an allograft of marrow or hematopoietic stem cell transplant (given that these patients carry a risk of aspergillosis, which in most cases appears after medullar recovery, they will not be included in the study). * Patients who received an autologous hematopoietic stem cell transplant (given that the duration of the neutropenia is often less than 10 days). * Patients who do not meet the inclusion criteria * Persons not covered by the national Health Insurance Agency
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| the variability of protein profiles | baseline |
Countries
France
Outcome results
None listed